We don’t support this browser anymore.
This means our website may not look and work as you would expect. Read more about browsers and how to update them here.

SenzaGen AB (SENZA) NPV

Sell:6.24 SEK Buy:6.32 SEK Change: 0.04 SEK (0.63%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:6.24 SEK
Buy:6.32 SEK
Change: 0.04 SEK (0.63%)
Prices delayed by at least 15 minutes | Switch to live prices |
Sell:6.24 SEK
Buy:6.32 SEK
Change: 0.04 SEK (0.63%)
Prices delayed by at least 15 minutes | Switch to live prices |
The selling price currently displayed is higher than the buying price. This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.

Business summary

SenzaGen AB is a Sweden-based company, which specializes in immunology, technology and genomics. The Company markets, sells and performs the in vitro Genomic Allergen Rapid Detection (GARD) sensitization test through its own laboratory and through licensed Contract Research Organization (CROs). SenzaGen AB makes it possible to replace animal experiments with in vitro genetic testing to determine the allergenicity of the chemicals people come in contact with in their daily lives, such as for example in cosmetics, pharmaceuticals, food products and dyes. The Company sells the tests in Sweden and the United States, and also sells through partners in several other countries. SenzaGen AB has a subsidiary in San Francisco, the United States.

Contact details

Address:
Medicon Village
Building 401, Scheelevagen 2
LUND
223 63
Sweden
Telephone:
+46 (46) 2756200
Website:
https://senzagen.com/

Important dates

Future events
There are no future events available.
Past events
There are no past events available.

General stock information

Short code:
SENZA
ISIN:
SE0010219626
Market cap:
154.32 million SEK
Shares in issue:
24.19 million
Sector:
Biotechnology
Exchange:
Stockholm Stock Exchange
Country:
Sweden
Currency:
Swedish Krona
Indices:
n/a

Key personnel

  • Carl Borrebaeck
    Chairman of the Board
  • Peter Nahlstedt
    Chief Executive Officer
  • Henrik Johansson
    Chief Scientific Officer
  • Marianne Olsson
    Vice President - Finance
  • Maria Agemark
    Vice President - Operations
  • Tina Dackemark Lawesson
    Vice President Marketing and Communications
  • Anna Cherouvrier Hansson
    Vice President - Business Development
  • Mikael Wahlgren
    Chief Legal Officer

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Business summary, contact details and key personnel provided by Thomson Reuters. Important dates provided by Digital Look Ltd. General stock information provided by Reuters.

Share

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.

Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.